Biotech

United States FDA Clears Mesoblast Limited (ASX:MSB) Phase 2 Trial For Cervical Spinal Fusion

🕔5/19/2010 10:17:16 AM

Australia's regenerative medicine company, Mesoblast Limited (ASX:MSB) (ADR:MBLTY), today announced that it has received clearance from the United States Food and Drug Administration (FDA) to begin Phase 2 clinical trials of its "off-the-shelf" or allogeneic stem cell product NeoFuse(TM) for fusion of the cervical spine in the neck. As with all of Mesoblast's previous Investigational New Drug (IND) submissions, FDA clearance was obtained within the minimum 30-day period.

Read Full Article▸

Mesoblast Limited (ASX:MSB) To Acquire Angioblast Systems Inc, Successfully Completes Capital Raise

🕔5/12/2010 1:53:22 PM

Australia's regenerative medicine company, Mesoblast Limited (ASX:MSB) (OTC:MBLTY) today announced that it will acquire its United States associate company, Angioblast Systems, Inc. (Angioblast). Additionally, Mesoblast announced it has completed a capital raising of A$37 million to fund the acquisition and advance operations of the expanded Mesoblast Group. These funds comprise A$24 million invested immediately and A$13 million committed subject to both shareholder approval and completion of the acquisition offer.

Read Full Article▸

Mesoblast Limited (ASX:MSB) Completes Enrolment For First Spinal Fusion Trial

🕔4/30/2010 5:08:29 PM

Australia's regenerative medicine company, Mesoblast Limited (ASX:MSB) (ADR:MBLTY),today announced it had cash reserves of $12.6 million for the reporting period ended 31 March 2010. The results are in line with expectations and reflect prudent cash management and tight control of resources.

Read Full Article▸

Benitec Limited (ASX:BLT) T Cell HIV Trial Open For Recruitment

🕔4/12/2010 2:23:16 PM

The Directors of Benitec Limited (ASX:BLT) (PINK:BNIKF) announced today that its second HIV-targeted clinical trial is open for recruitment following favourable review and approval of the protocol and associated documents by the Institutional Review Board of City of Hope, California, and the US Food and Drug Administration (FDA).

Read Full Article▸

Benitec Limited (ASX:BLT) Raises USD$6.0 Million via Convertible Note

🕔4/12/2010 10:13:16 AM

Benitec Limited (ASX:BLT) (PINK:BNIKF) are delighted to announce the signing of a convertible note facility with La Jolla Cove Investors, Inc. to provide up to US$6 million in funding. La Jolla Cove Investors, Inc. is a California (US) based private investment company that invests in small to mid sized market capitalised publicly traded companies. Benitec commenced discussions with La Jolla Cove Investors in January 2010 and over the last few months they have completed their due diligence and have agreed to provide this important investment.

Read Full Article▸

Mesoblast Limited (ASX:MSB) Market Exclusivity For Its Biologic Products Strengthened By New United States Health Care Act

🕔4/6/2010 10:38:31 AM

Australian regenerative medicine company and biologic innovator, Mesoblast Limited (ASX:MSB) (OTC:MBLTY), today provided an assessment on how the recently enacted United States Patient Protection and Affordable Care Act (HB 3590) is expected to have a positive impact on the commercial prospects for both Mesoblast and its United States-associated company, Angioblast Systems Inc.

Read Full Article▸

Benitec Limited (ASX:BLT) Announce A Board and Senior Management Update

🕔3/29/2010 10:54:56 AM

Benitec Limited (ASX:BLT) (PINK:BNIKF) announced today that Ms Sue MacLeman will step down from the role of Chief Executive Officer (CEO) and Managing Director to pursue other opportunities. She has agreed however to stay actively involved with Benitec as a Strategic Advisor at this exciting time for the Company. A transition arrangement has been put in place. Mr Mel Bridges and Dr John Chiplin will both move to Executive Director roles within the Company and the Board will be further strengthened in the coming months.

Read Full Article▸